News

Here's Why Shares in Recursion Pharmaceuticals Surged Today
Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion ...
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug
Rallybio (NASDAQ:RLYB) stock soars 114% after agreeing to sell its stake in a rare bone disorder asset, extending cash runway to mid-2027. Read more here.
Fierce Biotech6d
Rallybio shifts gears, cashing out of Recursion pact to extend runway
Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.
Zacks Investment Research on MSN4d
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.72, moving +2.24% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.28%.